Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-Term Care Facilities in England (VIVALDI)

Oliver Stirrup; Maria Krutikov; Gokhan Tut; Tom Palmer; David Bone; Rachel Bruton; Chris Fuller; Borscha Azmi; Tara Lancaster; Panagiota Sylla; Nayandeep Kaur; Eliska Spalkova; Christopher Bentley; Umayr Amin; Azar Jadir; Samuel Hulme; Rebecca Giddings; Hadjer Nacer-Laidi; Verity Baynton; Aidan Irwin-Singer; Andrew Hayward; Paul Moss; Andrew Copas; Laura Shallcross

doi:10.1093/infdis/jiac146

Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-Term Care Facilities in England (VIVALDI)

Oliver Stirrup, Maria Krutikov^*, Gokhan Tut, Tom Palmer, David Bone, Rachel Bruton, Chris Fuller, Borscha Azmi, Tara Lancaster, Panagiota Sylla, Nayandeep Kaur, Eliska Spalkova, Christopher Bentley, Umayr Amin, Azar Jadir, Samuel Hulme, Rebecca Giddings, Hadjer Nacer-Laidi, Verity Baynton, Aidan Irwin-SingerAndrew Hayward, Paul Moss, Andrew Copas, Laura Shallcross

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-Term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.

Original language	English
Pages (from-to)	1877-1881
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	226
Issue number	11
DOIs	https://doi.org/10.1093/infdis/jiac146
Publication status	Published - 1 Dec 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Keywords

COVID-19
antibodies
long-Term care facilities
vaccination
waning

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/jiac146

Cite this

Stirrup, O., Krutikov, M., Tut, G., Palmer, T., Bone, D., Bruton, R., Fuller, C., Azmi, B., Lancaster, T., Sylla, P., Kaur, N., Spalkova, E., Bentley, C., Amin, U., Jadir, A., Hulme, S., Giddings, R., Nacer-Laidi, H., Baynton, V., ... Shallcross, L. (2022). Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-Term Care Facilities in England (VIVALDI). Journal of Infectious Diseases, 226(11), 1877-1881. https://doi.org/10.1093/infdis/jiac146

@article{103a4030ed2a43339bebe8f573664110,

title = "Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-Term Care Facilities in England (VIVALDI)",

abstract = "General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-Term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.",

keywords = "COVID-19, antibodies, long-Term care facilities, vaccination, waning",

author = "Oliver Stirrup and Maria Krutikov and Gokhan Tut and Tom Palmer and David Bone and Rachel Bruton and Chris Fuller and Borscha Azmi and Tara Lancaster and Panagiota Sylla and Nayandeep Kaur and Eliska Spalkova and Christopher Bentley and Umayr Amin and Azar Jadir and Samuel Hulme and Rebecca Giddings and Hadjer Nacer-Laidi and Verity Baynton and Aidan Irwin-Singer and Andrew Hayward and Paul Moss and Andrew Copas and Laura Shallcross",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2022",

month = dec,

day = "1",

doi = "10.1093/infdis/jiac146",

language = "English",

volume = "226",

pages = "1877--1881",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "11",

}

Stirrup, O, Krutikov, M, Tut, G, Palmer, T, Bone, D, Bruton, R, Fuller, C, Azmi, B, Lancaster, T, Sylla, P, Kaur, N, Spalkova, E, Bentley, C, Amin, U, Jadir, A, Hulme, S, Giddings, R, Nacer-Laidi, H, Baynton, V , Irwin-Singer, A, Hayward, A, Moss, P, Copas, A & Shallcross, L 2022, 'Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-Term Care Facilities in England (VIVALDI)', Journal of Infectious Diseases, vol. 226, no. 11, pp. 1877-1881. https://doi.org/10.1093/infdis/jiac146

Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-Term Care Facilities in England (VIVALDI). / Stirrup, Oliver; Krutikov, Maria; Tut, Gokhan et al.
In: Journal of Infectious Diseases, Vol. 226, No. 11, 01.12.2022, p. 1877-1881.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-Term Care Facilities in England (VIVALDI)

AU - Stirrup, Oliver

AU - Krutikov, Maria

AU - Tut, Gokhan

AU - Palmer, Tom

AU - Bone, David

AU - Bruton, Rachel

AU - Fuller, Chris

AU - Azmi, Borscha

AU - Lancaster, Tara

AU - Sylla, Panagiota

AU - Kaur, Nayandeep

AU - Spalkova, Eliska

AU - Bentley, Christopher

AU - Amin, Umayr

AU - Jadir, Azar

AU - Hulme, Samuel

AU - Giddings, Rebecca

AU - Nacer-Laidi, Hadjer

AU - Baynton, Verity

AU - Irwin-Singer, Aidan

AU - Hayward, Andrew

AU - Moss, Paul

AU - Copas, Andrew

AU - Shallcross, Laura

PY - 2022/12/1

Y1 - 2022/12/1

N2 - General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-Term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.

AB - General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-Term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.

KW - COVID-19

KW - antibodies

KW - long-Term care facilities

KW - vaccination

KW - waning

UR - http://www.scopus.com/inward/record.url?scp=85133299608&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiac146

DO - 10.1093/infdis/jiac146

M3 - Article

C2 - 35429382

AN - SCOPUS:85133299608

SN - 0022-1899

VL - 226

SP - 1877

EP - 1881

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 11

ER -

Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-Term Care Facilities in England (VIVALDI)

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this